Agarwal P
Int J Trichology. 2024; 15(5):194-196.
PMID: 39170087
PMC: 11335045.
DOI: 10.4103/ijt.ijt_77_23.
Westerkam L, McShane D, Nieman E, Morrell D
Paediatr Drugs. 2024; 26(3):245-257.
PMID: 38466519
DOI: 10.1007/s40272-024-00620-2.
Quadri I, Reneau J, Hanel W, Chung C
Front Immunol. 2023; 14:1291259.
PMID: 38022633
PMC: 10654973.
DOI: 10.3389/fimmu.2023.1291259.
Gao L, Zhang H, Tan X, Wang Y, Song H, Yuan V
Biomolecules. 2023; 13(7).
PMID: 37509112
PMC: 10377598.
DOI: 10.3390/biom13071076.
Mattsson J, Israelsson E, Bjorhall K, Yrlid L, Thorn K, Thoren A
Skin Health Dis. 2023; 3(3):e209.
PMID: 37275428
PMC: 10233092.
DOI: 10.1002/ski2.209.
Impact and Management of Loss of Eyebrows and Eyelashes.
Starace M, Cedirian S, Alessandrini A, Bruni F, Quadrelli F, Melo D
Dermatol Ther (Heidelb). 2023; 13(6):1243-1253.
PMID: 37188989
PMC: 10264316.
DOI: 10.1007/s13555-023-00925-z.
Eyebrow and Eyelash Alopecia: A Clinical Review.
Nguyen B, Hu J, Tosti A
Am J Clin Dermatol. 2022; 24(1):55-67.
PMID: 36183302
PMC: 9870835.
DOI: 10.1007/s40257-022-00729-5.
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Glickman J, Del Duca E, Nia J, Hashim P, Singer G
Arch Dermatol Res. 2022; 315(2):181-189.
PMID: 35230488
DOI: 10.1007/s00403-022-02336-0.
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Dillon K
Clin Cosmet Investig Dermatol. 2021; 14:691-714.
PMID: 34211288
PMC: 8242127.
DOI: 10.2147/CCID.S309215.
Treatment of pediatric alopecia areata: A systematic review.
Barton V, Toussi A, Awasthi S, Kiuru M
J Am Acad Dermatol. 2021; 86(6):1318-1334.
PMID: 33940103
PMC: 8556406.
DOI: 10.1016/j.jaad.2021.04.077.
Current Treatment of Alopecia Areata.
Hordinsky M
J Investig Dermatol Symp Proc. 2020; 20(1):S28-S30.
PMID: 33099380
PMC: 11549921.
DOI: 10.1016/j.jisp.2020.04.004.
Identification of novel therapeutic targets for blocking acantholysis in pemphigus.
Burmester I, Flaswinkel S, Thies C, Kasprick A, Kamaguchi M, Bumiller-Bini V
Br J Pharmacol. 2020; 177(22):5114-5130.
PMID: 32815159
PMC: 7588822.
DOI: 10.1111/bph.15233.
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.
Elli E, Barate C, Mendicino F, Palandri F, Palumbo G
Front Oncol. 2019; 9:1186.
PMID: 31788449
PMC: 6854013.
DOI: 10.3389/fonc.2019.01186.
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
Montilla A, Gomez-Garcia F, Gomez-Arias P, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B
Dermatol Ther (Heidelb). 2019; 9(4):655-683.
PMID: 31606872
PMC: 6828894.
DOI: 10.1007/s13555-019-00329-y.
T-cell positioning by chemokines in autoimmune skin diseases.
Richmond J, Strassner J, Essien K, Harris J
Immunol Rev. 2019; 289(1):186-204.
PMID: 30977191
PMC: 6553463.
DOI: 10.1111/imr.12762.
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis G, McInnes I, Siebert S
Rheumatology (Oxford). 2019; 58(Suppl 1):i43-i54.
PMID: 30806709
PMC: 6390879.
DOI: 10.1093/rheumatology/key276.
Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes.
Craiglow B
JAAD Case Rep. 2018; 4(10):988-989.
PMID: 30417059
PMC: 6218694.
DOI: 10.1016/j.jdcr.2018.07.018.
Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K, Suchonwanit P
Drug Des Devel Ther. 2018; 12:2323-2335.
PMID: 30100707
PMC: 6067625.
DOI: 10.2147/DDDT.S172638.
Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Shivanna C, Shenoy C, Priya R
Int J Trichology. 2018; 10(3):103-107.
PMID: 30034188
PMC: 6028993.
DOI: 10.4103/ijt.ijt_21_18.
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz D, Kanno Y, Villarino A, Ward M, Gadina M, OShea J
Nat Rev Drug Discov. 2017; 17(1):78.
PMID: 29282366
PMC: 6168198.
DOI: 10.1038/nrd.2017.267.
